...
首页> 外文期刊>Neuromolecular medicine >Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells
【24h】

Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells

机译:miR-125b对原代胶质母细胞瘤CD133阴性细胞和CD133阳性细胞侵袭的功能差异

获取原文
获取原文并翻译 | 示例
           

摘要

MicroRNAs (miRNAs) are small noncoding RNAs whose function as modulators of gene expression is crucial for the proper control of cell development, differentiation, and homeostasis. The total number and composition of miRNAs expressed per cell at different stages of development varies widely, and the same miRNA may function differently at different stages of development. In this prospective study, we evaluated the function of miR- 125b at different developmental stages of glioblastoma cells, such as primary glioblastoma cells and the corresponding stem cells. CD133 is an important surface marker in glioblastoma stem cells. We found that the upregulation of miR-125b had no effects on the invasion of primary glioblastoma CD133-negative cells but that it could inhibit the invasion of corresponding CD133-positive cells; however, the downregulation of miR-125b also had no effects on the invasion of primary glioblastoma CD133-negative cells but promoted the invasion of CD133-positive cells. Further research into the underlying mechanism demonstrated that the effects of miR-125b on the invasion of glioblastoma CD133-positive cells were associated with the alteration of the expression of MMPs (MMP-2 and MMP-9) and corresponding inhibitors (RECK and TIMP3). Our results demonstrate that miR-125b expression plays an essential role in the invasion of glioblastoma CD133- positive cells but not CD133-negative cells. Therefore, miR-125b may represent a novel target for therapy targeting the invasion of glioblastoma stem cells in the future.
机译:微小RNA(miRNA)是小的非编码RNA,其作为基因表达调节剂的功能对于正确控制细胞发育,分化和体内平衡至关重要。每个细胞在不同发育阶段表达的miRNA的总数和组成差异很大,并且相同的miRNA在不同发育阶段的功能可能不同。在这项前瞻性研究中,我们评估了miR-125b在胶质母细胞瘤细胞(例如原发性胶质母细胞瘤细胞和相应的干细胞)不同发育阶段的功能。 CD133是胶质母细胞瘤干细胞中重要的表面标记。我们发现,miR-125b的上调对原发性胶质母细胞瘤CD133阴性细胞的侵袭没有影响,但可以抑制相应的CD133阳性细胞的侵袭。然而,miR-125b的下调对原发性胶质母细胞瘤CD133阴性细胞的侵袭也没有影响,但促进了CD133阳性细胞的侵袭。对潜在机制的进一步研究表明,miR-125b对胶质母细胞瘤CD133阳性细胞侵袭的影响与MMPs(MMP-2和MMP-9)和相应抑制剂(RECK和TIMP3)表达的改变有关。 。我们的结果表明,miR-125b表达在胶质母细胞瘤CD133阳性细胞而非CD133阴性细胞的侵袭中起重要作用。因此,miR-125b可能代表将来靶向胶质母细胞瘤干细胞侵袭的新型治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号